3,0
7 jan 2015
Anonieme werknemer
Voormalige werknemer
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Diversity in Oncology portfolio, very strong in oncology.
Minpunten
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.